News and Press Releases
Press releases
Theralase Increases Revenue 23% for 1Q 2017 Financial Statements
Press ReleaseToronto, Ontario – May 30, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the deve...
Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer
Press ReleaseToronto, Ontario – May 26, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and th...
Theralase Reports Fiscal Year 2016 Financial Statements
Press ReleaseToronto, Ontario – May 1, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the develop...
Theralase PDT Technology Used to Treat Third Patient for Bladder Cancer
Press ReleaseToronto, Ontario – April 20, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the de...
Theralase Grants Stock Options
Press ReleaseToronto, Ontario – April 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the devel...
Theralase PDT Technology Used to Treat Second Patient for Bladder Cancer
Press ReleaseToronto, Ontario – April 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the de...
Theralase Affiliated Researchers to Present at International Conference
Press ReleaseToronto, Ontario – April 12, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the devel...
Theralase Announces Acceptance of Peer Reviewed Publication for Next Generation Anti-Cancer Drugs
Press ReleaseToronto, Ontario – April 6, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the develo...
Theralase PDT Technology Used to Treat First Patient for Bladder Cancer
Press ReleaseToronto, Ontario – April 4, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the de...
Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug
Press ReleaseToronto, Ontario – March 15, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the deve...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
